Literature DB >> 18855919

Prostate cancer risk assessment: choosing the sharpest tool in the shed.

Matthew R Cooperberg.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18855919      PMCID： PMC2948568          DOI： 10.1002/cncr.23920

Source DB:  PubMed          Journal:  Cancer        ISSN： 0008-543X            Impact factor:   6.860


× No keyword cloud information.
  17 in total

1.  External validation of University of California, San Francisco, Cancer of the Prostate Risk Assessment score.

Authors:  Kevin H Zhao; David J Hernandez; Misop Han; Elizabeth B Humphreys; Leslie A Mangold; Alan W Partin
Journal:  Urology       Date:  2008-04-18       Impact factor: 2.649

2.  Validation study of the accuracy of a postoperative nomogram for recurrence after radical prostatectomy for localized prostate cancer.

Authors:  Markus Graefen; Pierre I Karakiewicz; Ilias Cagiannos; Eric Klein; Patrick A Kupelian; David I Quinn; Susan M Henshall; John J Grygiel; Robert L Sutherland; Phillip D Stricker; Jean de Kernion; Thomas Cangiano; Fritz H Schröder; Mark F Wildhagen; Peter T Scardino; Michael W Kattan
Journal:  J Clin Oncol       Date:  2002-02-15       Impact factor: 44.544

3.  A validation of two preoperative nomograms predicting recurrence following radical prostatectomy in a cohort of European men.

Authors:  Markus Graefen; Pierre I Karakiewicz; Ilias Cagiannos; Peter G Hammerer; Alexander Haese; Jüri Palisaar; Salvador Fernandez; Jochen Noldus; Andreas Erbersdobler; Hartwig Huland; Peter T Scardino; Michael W Kattan
Journal:  Urol Oncol       Date:  2002 Jul-Aug       Impact factor: 3.498

4.  How well does the Partin nomogram predict pathological stage after radical prostatectomy in a community based population? Results of the cancer of the prostate strategic urological research endeavor.

Authors:  David F Penson; Gary D Grossfeld; Yu-Ping Li; James M Henning; Deborah P Lubeck; Peter R Carroll
Journal:  J Urol       Date:  2002-04       Impact factor: 7.450

5.  International validation of a preoperative nomogram for prostate cancer recurrence after radical prostatectomy.

Authors:  Markus Graefen; Pierre I Karakiewicz; Ilias Cagiannos; David I Quinn; Susan M Henshall; John J Grygiel; Robert L Sutherland; Phillip D Stricker; Eric Klein; Patrick Kupelian; Donald G Skinner; Gary Lieskovsky; Bernard Bochner; Hartwig Huland; Peter G Hammerer; Alexander Haese; Andreas Erbersdobler; James A Eastham; Jean de Kernion; Thomas Cangiano; Fritz H Schröder; Mark F Wildhagen; Theo H van der Kwast; Peter T Scardino; Michael W Kattan
Journal:  J Clin Oncol       Date:  2002-08-01       Impact factor: 44.544

6.  Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era.

Authors:  Anthony V D'Amico; Judd Moul; Peter R Carroll; Leon Sun; Deborah Lubeck; Ming-Hui Chen
Journal:  J Clin Oncol       Date:  2003-06-01       Impact factor: 44.544

7.  Pretreatment nomogram that predicts 5-year probability of metastasis following three-dimensional conformal radiation therapy for localized prostate cancer.

Authors:  Michael W Kattan; Michael J Zelefsky; Patrick A Kupelian; Daniel Cho; Peter T Scardino; Zvi Fuks; Steven A Leibel
Journal:  J Clin Oncol       Date:  2003-12-15       Impact factor: 44.544

8.  Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era.

Authors:  Andrew J Stephenson; Michael W Kattan; James A Eastham; Fernando J Bianco; Ofer Yossepowitch; Andrew J Vickers; Eric A Klein; David P Wood; Peter T Scardino
Journal:  J Clin Oncol       Date:  2009-07-27       Impact factor: 44.544

9.  Validation of the Kattan preoperative nomogram for prostate cancer recurrence using a community based cohort: results from cancer of the prostate strategic urological research endeavor (capsure).

Authors:  Kirsten L Greene; Maxwell V Meng; Eric P Elkin; Matthew R Cooperberg; David J Pasta; Michael W Kattan; Katrine Wallace; Peter R Carroll
Journal:  J Urol       Date:  2004-06       Impact factor: 7.450

10.  Time trends in clinical risk stratification for prostate cancer: implications for outcomes (data from CaPSURE).

Authors:  Matthew R Cooperberg; Deborah P Lubeck; Shilpa S Mehta; Peter R Carroll
Journal:  J Urol       Date:  2003-12       Impact factor: 7.450
View more
  4 in total

Review 1.  Reporting performance of prognostic models in cancer: a review.

Authors:  Susan Mallett; Patrick Royston; Rachel Waters; Susan Dutton; Douglas G Altman
Journal:  BMC Med       Date:  2010-03-30       Impact factor: 8.775

2.  Risk assessment for prostate cancer metastasis and mortality at the time of diagnosis.

Authors:  Matthew R Cooperberg; Jeanette M Broering; Peter R Carroll
Journal:  J Natl Cancer Inst       Date:  2009-06-09       Impact factor: 13.506

Review 3.  Tissue-Based Biomarkers for the Risk Stratification of Men With Clinically Localized Prostate Cancer.

Authors:  Spyridon P Basourakos; Michael Tzeng; Patrick J Lewicki; Krishnan Patel; Bashir Al Hussein Al Awamlh; Siv Venkat; Jonathan E Shoag; Michael A Gorin; Christopher E Barbieri; Jim C Hu
Journal:  Front Oncol       Date:  2021-05-28       Impact factor: 6.244

4.  The value of personalised risk information: a qualitative study of the perceptions of patients with prostate cancer.

Authors:  Paul K J Han; Norbert Hootsmans; Michael Neilson; Bethany Roy; Terence Kungel; Caitlin Gutheil; Michael Diefenbach; Moritz Hansen
Journal:  BMJ Open       Date:  2013-09-13       Impact factor: 2.692
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.